Health
Lilly Alzheimer’s Drug Seen Effective by FDA Advisory Panel
- If approved, Lilly’s drug would go up against Leqembi
- Donanemab has encountered obstacles on path to approval
This article is for subscribers only.
Eli Lilly & Co.’s drug for Alzheimer’s has benefits that outweigh its risks, US drug regulatory advisers said, bringing the treatment’s long path to the market closer to a successful end.
Eleven advisers to the Food and Drug Administration voted unanimously on Monday that Lilly’s donanemab helps patients in the early stages of Alzheimer’s disease, and that those benefits outweight the drug’s risks. The FDA is expected to make a final decision on donanemab by the end of the year.